December 2018 Forms Instruction Manual Updates

In case you missed them, here are the changes made to the Forms Instruction Manual during the month of December. Check the "Getting Started" page of the Forms Instruction Manual for a list of the most recent updates. Updates made after March 2015 are always available for reference in the "Historical Manual Updates" section.

<table>
<thead>
<tr>
<th>Date</th>
<th>Manual Section</th>
<th>Add/Remove/Modify</th>
<th>Description</th>
</tr>
</thead>
</table>
| 12/21/18   | 2116: PCT Post-HCT | Remove           | Removed the following blue note box instruction (struck out below) for questions 30 and 126 regarding Flow Cytometry reporting for Myeloma. These assessments can now be reported in the same way as all other disease assessments.  

**An exception of the note above applies to multiple myeloma** If the flow cytometry assessment has < 5% malignant plasma cells, this result should not be reported because the result is not reliable; if no other cytogenetic or FISH assessments were performed, report "no." However, if the flow cytometry assessment found ≥ 5% malignant plasma cells, this should be reported as evidence of disease. |
| 12/21/18   | 2450: Post-TED | Remove           | Removed the following blue note box instruction (struck out below) above question 82 regarding Flow Cytometry reporting for Lymphoma and Myeloma. These assessments can now be reported in the same way as all other disease assessments.  

**Myeloma and Lymphoma** Flow cytometry assessments performed to detect myeloma or lymphoma should not be reported if negative (< 5% malignant cells detected). If flow cytometry was performed to detect myeloma or lymphoma and showed less than 5% malignant cells, report "not applicable" for question 82 and go to question 85. |
| 12/13/2018 | Toxicities     | Modify           | Added clarification on how hypogammaglobulinemia is documented: Report the date (YYYY-MM-DD) in question 126 when the hypogammaglobulinemia was documented by either a physician/health care provider or determined by lab results. |
| 12/3/18    | Multiple Myeloma Response Criteria | Modify           | Separated the blue note box regarding urine studies to better reflect requirements needed for sCR and CR versus requirements needed for nCR, VGPR, and PR. |
### Amyloidosis Response Criteria

**Add**

Added further clarification for the Renal Response criteria (indicated in *red* below):

- ≥ 50% decrease of at least 0.5 g/day (500mg/24hr) in 24-hour urine protein of > 0.5 g/day (500mg/24hr) pre-treatment and
- Creatinine clearance must not have worsened by ≥ 25% over baseline

### 2400: Pre-TED

**Modify**

Updated link in the 2400 Pre-TED to reflect current reporting instructions for autologous transplants.

---

Questions, feedback, or requests may be submitted directly on the manual website using the Feedback Feature at the bottom of each page. For more information on how to submit feedback, [click here](#).